【摘 要】
：
Biologic markers that predict presence or subsequent development of invasive disease in patents diagnosed with ductal carcinoma in-situ (DCIS) are needed for more personalized targeted treatment.Subcl
【机 构】
：
Department of Pathology and Laboratory Medicine School of Medicine University of Pennsylvania USA
【出 处】
：
(BITs 3rd Annual World Cancer Congress-2010, Breast Cancer C
论文部分内容阅读
Biologic markers that predict presence or subsequent development of invasive disease in patents diagnosed with ductal carcinoma in-situ (DCIS) are needed for more personalized targeted treatment.Subclassification of breast cancer based on cDNA expression profile which could be reflected by immunohistochemical detection for ER, PR and HER-2/neu,have recently been shown to have prognostic significances in invasive disease.The implication of the similar phenotypic patterns in ductal carcinoma in situ (DCIS) remains uncertain.In this presentation, data from a study based on 104 patients who had DCIS on clinical and imaging study initially will be presented.The incidence of early invasive disease in this group of patients was analyzed in association with the immunphenotypic classification and various histopathologic features of the DCIS.The prognostic and therapeutic significance of HER2 overexpression and ER/PR/HER2 phenotype in DCIS will be discussed.A HER2 vaccine therapy which is currently in clinical trial phase in the Hospital of the University of Pennsylvania will be briefly reviewed and its potential impact on early invasive disease will be discussed.
其他文献
Progression and metastasis represent the most detrimental factors of cancer mortality.To sustain progression and metastasis, tumors including breast cancers absolutely depend on the establishment of n
Dr.Roberts will address general questions arising firom his long standing interests in kinases in cancer, with a particular emphasis on the PI3Kinase pathway.
African-American (AA) and premenopausal patients have been shown to have poorer stage for stage survival than the overall population.Hispanic females at our institution have been found to have lower g
Women carrying germline BRCA1/2 deleterious mutations are an extreme risk population for developing breast cancer,with a cumulative life-time risk of 56-80%.Prophylactic bilateral mastectomy provides
Breast carcinomas are highly heterogeneous, with many different pathological subtypes and recently described molecular subtypes.This heterogeneity among tumors occurring in different patients should n
Gene expression profiling using microarrays combined with qPCR has created new possibilities for the molecular characterisation of breast cancer.We have completed whole genome microarray analysis of >
Since the diagnostic value of the vessel parameters maximum velocity, pulsatility index and min RI has been found to be limited, power Doppler, a different method of signal processing, was developed t
Breast cancer is the commonest type of malignancy to affect women in western countries.In India, is the commonest cancer to affect women of metropolitan cities with over 80,000 new cases diagnosed eac
In 2006, the American Cancer Society estimated that one in eight women in the US was diagnosed with breast cancer,making the illness the second leading cause of death among women, after lung cancer.Al
High-resolution MRI, particularly dynamic contrast-enhanced MRI (DCE-MRI), provides high sensitivity for the detection of breast lesions and is routinely used on clinical (1.5 Tesla) scanners.Recent s